ASCVD 10-Year Heart Risk Estimator
Estimate 10-year risk of primary hard atherosclerotic cardiovascular events (MI, stroke, CHD death) for adults aged 40–79.
Discuss Risk Enhancers. Consider Moderate-Intensity Statin if present.
Medsy calculates ASCVD risk automatically during patient intake and highlights lipid targets.
Explore Medsy EMR →ACC/AHA 10-Year ASCVD Risk Category & Statin Guidance
| Risk Category | 10-Year ASCVD Risk Score | Clinical Primary Recommendation |
|---|---|---|
| Low Risk | < 5.0% | Emphasize healthy lifestyle behaviors (diet, exercise). |
| Borderline Risk | 5.0% – 7.4% | If risk enhancers present, consider moderate-intensity statin. |
| Intermediate Risk | 7.5% – 19.9% | Initiate moderate-intensity statin therapy (target LDL reduction 30-49%). |
| High Risk | ≥ 20.0% | Initiate high-intensity statin therapy (target LDL reduction ≥ 50%). |
Key ASCVD Risk Enhancers
When risk decision is borderline or intermediate, clinicians evaluate risk enhancers such as family history of premature ASCVD, persistent LDL-C ≥ 160 mg/dL, metabolic syndrome, chronic kidney disease, inflammatory diseases (rheumatoid arthritis, HIV), and high-sensitivity CRP ≥ 2.0 mg/L.
Intended Clinical Population
This estimator applies to primary prevention patients aged 40 to 79 without pre-existing clinical ASCVD. Patients with baseline LDL-C ≥ 190 mg/dL should receive high-intensity statin therapy without requiring ASCVD score calculation.